My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2024_OpioidSettlemtAgrmt_JanssenJJ
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
2024_OpioidSettlemtAgrmt_JanssenJJ
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
4/11/2024 1:10:33 PM
Creation date
4/11/2024 1:08:48 PM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
127
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
<br />C-5 <br /> <br /> <br />c. Sponsoring, or otherwise providing financial support or In-Kind Support to <br />medical education programs that Promote Products for the Treatment of <br />Opioid-induced Side Effects; <br />d. Creating, sponsoring, or otherwise providing financial support or In-Kind <br />Support for advertisements that Promote Products for the Treatment of <br />Opioid-induced Side Effects, including but not limited to internet <br />advertisements or similar content, and providing hyperlinks or otherwise <br />directing internet traffic to advertisements. <br />4. Notwithstanding subsection C, Janssen may Promote Products for the Treatment of <br />Opioid-induced Side Effects so long as such Promotion does not associate the <br />product with Opioids or Opioid Products. <br />5. Treatment of Pain <br />a. Janssen shall not, either through Janssen or through Third Parties, engage in <br />any conduct that Promotes the Treatment of Pain, except that Janssen may <br />continue to Promote the Treatment of Pain with branded non-Opioids, <br />including Tylenol and Motrin. <br />b. Janssen shall not, either through Janssen or through Third Parties, engage in <br />any conduct that Promotes the concept that pain is undertreated, except in <br />connection with Promoting the use of branded non-Opioids, including <br />Tylenol and Motrin, for the Treatment of Pain. <br />c. Janssen shall not disseminate Unbranded Information, including Unbranded <br />Information about a medical condition or disease state, that contains links to <br />branded information about Opioid Products or that otherwise Promotes <br />Opioids or Opioid Products. <br />6. Notwithstanding subsection C.5 above: <br />a. Janssen may Promote or provide educational information about the Treatment <br />of Pain with non-Opioids or therapies such as acetaminophen or non-steroidal <br />anti-inflammatory drugs (NSAIDS), including Promoting or providing <br />educational information about such non-Opioids or therapies as alternatives <br />to Opioid use, or as part of multimodal therapy which may include Opioid <br />use, so long as such non-Opioid Promotional or educational information does <br />not Promote Opioids or Opioid Products. <br />b. Janssen may provide educational information about the Treatment of Pain <br />related to medical procedures involving devices manufactured or sold by <br />Janssen, including educational information about Opioids or Opioid Products, <br />so long as such information does not Promote Opioids or Opioid Products.
The URL can be used to link to this page
Your browser does not support the video tag.